The Efficacy Evaluation of Guizhi Decoction and Yupingfeng Powder in the Treatment of Chronic Urticaria with Nutritive Qi and Defensive Qi Disharmony Syndrome

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400090145

Enrollment

Unknown

Registered

2024-09-25

Start date

2024-04-03

Completion date

Unknown

Last updated

2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Urticaria

Interventions

experimental group:Combination of Fexofenadine Hydrochloride Tablets with Guizhi Decoction and Yupingfeng Powder

control group:Fexofenadine Hydrochloride Tablets

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Meeting Western medical diagnostic criteria and traditional Chinese medicine syndrome differentiation diagnostic criteria; (2) Age between 18 and 65 years old; (3) No use of glucocorticoids, immunosuppressants, or biologics for the past 4 weeks; (4) The subjects have signed an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Those who do not meet the diagnostic criteria or have a different traditional Chinese medicine syndrome differentiation; (2) Patients with other serious primary diseases in the circulatory, respiratory, digestive, urinary systems, tumors, and mental illnesses; (3) Acute urticaria, urticarial vasculitis, urticarial drug rash, vascular edema type of urticaria; (4) Various inducible urticarias, including physical urticarias (dermographism), cold-induced urticaria, heat-induced urticaria, delayed pressure urticaria, solar urticaria, vibratory angioedema, cholinergic urticaria, aquagenic urticaria, and contact urticaria; (5) Hyperimmunoglobulin E syndrome, mastocytosis, systemic lupus erythematosus; (6) Pregnant, lactating, or planning to become pregnant within 3 months; (7) Currently participating in other drug clinical trials or participated in other clinical trials within the past month; (8) History of allergy to drugs used in this trial; (9) Participants deemed unsuitable by the investigator.

Design outcomes

Primary

Measure	Time frame
Urticaria Activity Score 7;	—

Secondary

Measure	Time frame
Chronic Urticarial Quality of Life Questionnaire;Urticaria Control Test;Serum total IgE;C-reactive protein,CRP;Recurrence rate;	—

Countries

China

Contacts

Public ContactZhao Yiding

Shaanxi Provincial Hospital of Chinese Medicine

zhaoyiding2083@126.com+86 29 8725 1604

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026